Related Experiment Video
Updated: May 15, 2026
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip
Zhe Zhao1, Jie Wang2, Xuan Xiong1,3
1CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Jiangsu, China.
Abstract:
Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.
Insights
A new microwell platform rapidly generates micro-tumorspheres from breast cancer (BRC) biopsies. This method effectively enriches cancer stem cells (CSCs) for personalized drug testing and predicting patient outcomes.
Area of Science:
- Oncology
- Biotechnology
- Cell Biology
Background:
- Cancer stem cells (CSCs) are key drivers of breast cancer (BRC) initiation, progression, metastasis, and therapy resistance.
- Evaluating drug efficacy using patient-derived CSCs is crucial for advancing precision oncology.
- Current methods for isolating functional CSCs from limited clinical samples are challenging and not high-throughput.
Purpose of the Study:
- To develop a novel microwell cell-chip culture platform for rapid, high-throughput generation of uniform micro-tumorspheres (MTSs).
- To facilitate functional CSC enrichment and personalized drug testing from limited BRC specimens.
- To validate MTSs as a reliable model for assessing CSC functionality and predicting clinical outcomes.
Main Methods:
- Development of a microwell cell-chip platform for culturing limited BRC specimens.
- Generation of uniform micro-tumorspheres (MTSs) from puncture biopsies.
- Utilizing single-cell transcriptomics and limiting dilution tumor initiation assays to analyze MTSs.
- Testing the predictive accuracy of MTSs against clinical outcomes in BRC patients.
Main Results:
- The platform enables rapid (within 8 days) and high-throughput generation of uniform MTSs from small BRC samples.
- MTSs successfully recapitulate CSC functionality, uniformity, and heterogeneity, confirmed by transcriptomics and functional assays.
- MTSs demonstrated high accuracy (~93.8%) in predicting clinical outcomes for 16 BRC patients.
Conclusions:
- The developed microwell platform provides a robust and efficient tool for CSC enrichment and functional assessment.
- MTSs serve as a valuable in vitro model for personalized drug testing in breast cancer.
- This technology holds significant translational potential for advancing CSC-targeted precision medicine in oncology.
